Skip to main content
BLFS
NASDAQ Industrial Applications And Services

BioLife Solutions Exceeds Full Year 2025 Revenue Guidance with Strong Q4 Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$25.65
Mkt Cap
$1.201B
52W Low
$19.1
52W High
$29.62
52W Position info
34% above low
Off High info
13% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

BLFS sits 34% above its 52-week low of $19.1.

Summary

BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth.


Key Events · Earnings and Guidance · BLFS

  • Exceeded Full Year Revenue Guidance

    Preliminary unaudited revenue from continuing operations for 2025 reached $96.2 million, surpassing the high end of the adjusted guidance range of $95.0 million to $96.0 million.

  • Strong Q4 Revenue Growth

    Fourth quarter 2025 preliminary revenue from continuing operations was $24.8 million, a 20% increase compared to $20.7 million in the prior year's fourth quarter.

  • Significant Annual Growth

    Full year 2025 revenue from continuing operations increased 29% to $96.2 million from $74.6 million in 2024.

  • Positive 2026 Outlook

    The company anticipates revenue growth across its product portfolio and further expansion of adjusted EBITDA margin in 2026, with full guidance expected in February.


Analysis · BLFS · Industrial Applications And Services

BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth. The company's preliminary full-year 2025 revenue of $96.2 million surpassed the high end of its adjusted guidance range, indicating strong operational performance. The 20% year-over-year revenue growth in Q4 2025 and 29% for the full year from continuing operations highlight robust demand for its cell processing tools and services. This positive financial update, coupled with the strategic divestitures to become a pure-play cell processing company, positions BioLife Solutions for anticipated profitable growth and margin expansion in 2026.

How filings like this one have moved

In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLFS was trading at $25.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $19.10 to $29.62. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLFS - Latest Insights

BLFS
Sep 09, 2026, 5:22 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $34.93
Real-time Price: $34.95 info
Change: +$0.020 (+0.06%) info
Market Cap: $1.71B info
BLFS
Sep 09, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.93
Real-time Price: $34.95 info
Change: +$0.020 (+0.06%) info
Market Cap: $1.71B info
BLFS
Sep 04, 2026, 5:23 PM EDT
Filing Type: DEFM14A
Importance Score:
8
Price at Filing: $35.25
Real-time Price: $34.95 info
Change: -$0.300 (-0.85%) info
Market Cap: $1.71B info
BLFS
Aug 06, 2026, 4:22 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.93
Real-time Price: $34.95 info
Change: +$1.02 (+3%) info
Market Cap: $1.71B info
BLFS
Aug 06, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.93
Real-time Price: $34.95 info
Change: +$1.02 (+3%) info
Market Cap: $1.71B info